ALK and non-small cell lung carcinoma: We also observed a tendency toward high YAP expression in pretreatment specimens among non‐responders (SD or PD) to ALK inhibitors than among responders, highlighting the capability of YAP as a survival input for ALK‐rearranged NSCLC.